Dyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company develops a program that will focus on using antibody-oligo conjugates to block the repetitive DNA mutations that cause the disease myotonic dystrophy type 1.
|Employees (est.) (Mar 2020)||30||(+4%)|
Dyne Therapeutics total Funding
Dyne Therapeutics latest funding size
Time since last funding
|a year ago|
Dyne Therapeutics investors
|Atlas Venture, MPM Capital, Forbion Capital Partners|
Dyne Therapeutics has 217 Twitter Followers. The number of followers has increased 9.5% month over month and increased 19.3% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Dyne Therapeutics founded?
Dyne Therapeutics was founded in 2018.
Who are Dyne Therapeutics key executives?
Dyne Therapeutics's key executives are Mo Qatanani and Jonathan McNeill.
How many employees does Dyne Therapeutics have?
Dyne Therapeutics has 30 employees.
Who are Dyne Therapeutics competitors?
Competitors of Dyne Therapeutics include Ambrx, ProQR Therapeutics and Fulgent Genetics.
Where is Dyne Therapeutics headquarters?
Dyne Therapeutics headquarters is located at 830 Winter St, Waltham.
Where are Dyne Therapeutics offices?
Dyne Therapeutics has an office in Waltham.
How many offices does Dyne Therapeutics have?
Dyne Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies